Skip to main content

BENLYSTA

NDC 49401-088 · GlaxoSmithKline LLC

Generic namebelimumab
Dosage formSOLUTION
RouteSUBCUTANEOUS
Active ingredient(s)BELIMUMAB
Strength200 mg/mL
Pharmacologic classB Lymphocyte Stimulator-directed Antibody Interactions [MoA], B Lymphocyte Stimulator-specific Inhibitor [EPC], Decreased B Lymphocyte Activation [PE]
Marketing categoryBLA

Packages

49401-088-02 — 1 SYRINGE in 1 CARTON (49401-088-02) / 1 mL in 1 SYRINGE (49401-088-01)

49401-088-35 — 4 SYRINGE in 1 CARTON (49401-088-35) / 1 mL in 1 SYRINGE (49401-088-01)

49401-088-47 — 4 SYRINGE in 1 CARTON (49401-088-47) / 1 mL in 1 SYRINGE (49401-088-42)

49401-088-50 — 1 SYRINGE in 1 CARTON (49401-088-50) / 1 mL in 1 SYRINGE (49401-088-42)

49401-088-61 — 1 SYRINGE in 1 CARTON (49401-088-61) / 1 mL in 1 SYRINGE

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

49401-101 — belimumab, 49401-102 — belimumab

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q4 (October 2026 release). All data sources · How to read the labels

Current data releases:ICD-10-CM FY2027 · ICD-10-PCS FY2027 · HCPCS October 2026 · MS-DRG v44 · Medicare Code Editor v44.0 · NCCI PTP Q4 2026 · MUE Q4 2026 · NCD code lists 2026-01 · LCD export September 28, 2026 · All releases and sources